Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00124587" target="_blank" >RIV/00216224:14110/19:00124587 - isvavai.cz</a>
Výsledek na webu
<a href="https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-019-0179-6" target="_blank" >https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-019-0179-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s40942-019-0179-6" target="_blank" >10.1186/s40942-019-0179-6</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy
Popis výsledku v původním jazyce
BackgroundElevated serum vascular endothelial growth factor (VEGF) levels are associated with diabetic retinopathy (DR). Serum VEGF levels correlate with vitreous levels. Neuroretinal changes occur even before the appearance of vascular signs in DR. Role of VEGF as a biomarker for DR has not been assessed. Serum VEGF as a biomarker for severity of DR, was evaluated for the first time.MethodsConsecutive cases of type 2 diabetes mellitus [without DR, (no DR, n=38); non-proliferative DR, (NPDR, n=38); proliferative DR, (PDR, n=40)] and healthy controls (n=40) were included. Serum VEGF was measured using enzyme linked immunosorbent assay. Accuracy of VEGF as a biomarker for severity of retinopathy was measured using the area under the receiver operator characteristic (ROC) curve.ResultsSerum VEGF levels in controls, No DR, NPDR and PDR groups showed significant incremental trend from 138.96 +/- 63.37 pg/ml (controls) to 457.18 +/- 165.69 pg/ml (PDR) (F=48.47; p<0.001). Serum VEGF levels were observed to be significantly elevated even before DR had set in clinically. ROC for serum VEGF levels was significant in discriminating between the cases and the controls and had good accuracy in discerning between subjects with and without retinopathy. The area under curve (AUC +/- SE) for discrimination was significant: (a) cases and controls (n=156): AUC=0.858 +/- 0.029, p<0.001; (b) DR (NPDR+PDR) and No DR (n=116): AUC=0.791 +/- 0.044, p<0.001; and (c) NPDR and PDR (n=78): AUC=0.761 +/- 0.056, p<0.001, with over 90% projected sensitivity and specificity at various cut off values.Conclusion Serum VEGF level is a simple, effective laboratory investigative test in predicting the onset of DR in eyes showing no evidence of DR and serves as a reliable biomolecular biomarker for severity of DR.
Název v anglickém jazyce
Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy
Popis výsledku anglicky
BackgroundElevated serum vascular endothelial growth factor (VEGF) levels are associated with diabetic retinopathy (DR). Serum VEGF levels correlate with vitreous levels. Neuroretinal changes occur even before the appearance of vascular signs in DR. Role of VEGF as a biomarker for DR has not been assessed. Serum VEGF as a biomarker for severity of DR, was evaluated for the first time.MethodsConsecutive cases of type 2 diabetes mellitus [without DR, (no DR, n=38); non-proliferative DR, (NPDR, n=38); proliferative DR, (PDR, n=40)] and healthy controls (n=40) were included. Serum VEGF was measured using enzyme linked immunosorbent assay. Accuracy of VEGF as a biomarker for severity of retinopathy was measured using the area under the receiver operator characteristic (ROC) curve.ResultsSerum VEGF levels in controls, No DR, NPDR and PDR groups showed significant incremental trend from 138.96 +/- 63.37 pg/ml (controls) to 457.18 +/- 165.69 pg/ml (PDR) (F=48.47; p<0.001). Serum VEGF levels were observed to be significantly elevated even before DR had set in clinically. ROC for serum VEGF levels was significant in discriminating between the cases and the controls and had good accuracy in discerning between subjects with and without retinopathy. The area under curve (AUC +/- SE) for discrimination was significant: (a) cases and controls (n=156): AUC=0.858 +/- 0.029, p<0.001; (b) DR (NPDR+PDR) and No DR (n=116): AUC=0.791 +/- 0.044, p<0.001; and (c) NPDR and PDR (n=78): AUC=0.761 +/- 0.056, p<0.001, with over 90% projected sensitivity and specificity at various cut off values.Conclusion Serum VEGF level is a simple, effective laboratory investigative test in predicting the onset of DR in eyes showing no evidence of DR and serves as a reliable biomolecular biomarker for severity of DR.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30212 - Surgery
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
INTERNATIONAL JOURNAL OF RETINA AND VITREOUS
ISSN
2056-9920
e-ISSN
2056-9920
Svazek periodika
5
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
6
Strana od-do
1-6
Kód UT WoS článku
000693102600023
EID výsledku v databázi Scopus
2-s2.0-85073051045